Additionally, using CRISPR to target HER2 genes in breast cancer cells with overexpression of this oncogene has proven to be a successful method to impede their growth, and this effect seemed to be mediated through a dominant negative mutation (Wang and Sun, 2017). This evidence concerns the gene ERBB2 and breast carcinoma.